EE200200549A - Jagatud doosi teraapia veresooni kahjustava aktiivsusega - Google Patents
Jagatud doosi teraapia veresooni kahjustava aktiivsusegaInfo
- Publication number
- EE200200549A EE200200549A EEP200200549A EEP200200549A EE200200549A EE 200200549 A EE200200549 A EE 200200549A EE P200200549 A EEP200200549 A EE P200200549A EE P200200549 A EEP200200549 A EE P200200549A EE 200200549 A EE200200549 A EE 200200549A
- Authority
- EE
- Estonia
- Prior art keywords
- vascular damaging
- dose therapy
- split dose
- damaging activity
- damaging agent
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0038—Radiosensitizing, i.e. administration of pharmaceutical agents that enhance the effect of radiotherapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0007740A GB0007740D0 (en) | 2000-03-31 | 2000-03-31 | Combination therapy |
GB0013928A GB0013928D0 (en) | 2000-06-08 | 2000-06-08 | Methods of treatment |
GB0014904A GB0014904D0 (en) | 2000-06-20 | 2000-06-20 | Methods of treatment |
PCT/GB2001/001329 WO2001074369A1 (en) | 2000-03-31 | 2001-03-27 | Divided dose therapies with vascular damaging activity |
Publications (1)
Publication Number | Publication Date |
---|---|
EE200200549A true EE200200549A (et) | 2004-02-16 |
Family
ID=27255635
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EEP200200549A EE200200549A (et) | 2000-03-31 | 2001-03-27 | Jagatud doosi teraapia veresooni kahjustava aktiivsusega |
Country Status (23)
Country | Link |
---|---|
US (1) | US20030055024A1 (et) |
EP (1) | EP1272200B1 (et) |
JP (1) | JP2003528921A (et) |
KR (1) | KR20020084267A (et) |
CN (1) | CN1422157A (et) |
AT (1) | ATE298240T1 (et) |
AU (2) | AU4258601A (et) |
BR (1) | BR0109671A (et) |
CA (1) | CA2402078A1 (et) |
CZ (1) | CZ20023231A3 (et) |
DE (1) | DE60111622T2 (et) |
EE (1) | EE200200549A (et) |
ES (1) | ES2243466T3 (et) |
HU (1) | HUP0300576A3 (et) |
IL (1) | IL151627A0 (et) |
IS (1) | IS6555A (et) |
MX (1) | MXPA02009603A (et) |
NO (1) | NO20024683L (et) |
NZ (1) | NZ534190A (et) |
PL (1) | PL357282A1 (et) |
PT (1) | PT1272200E (et) |
SK (1) | SK13902002A3 (et) |
WO (1) | WO2001074369A1 (et) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EE200200565A (et) * | 2000-03-31 | 2004-06-15 | Angiogene Pharmaceuticals Ltd. | Vaskulaarse kahjustava toimega kombinatsioonravi |
US20040067255A1 (en) * | 2002-10-07 | 2004-04-08 | Chaplin David J. | Method of administering split doses of a vascular targeting agent |
GB0223379D0 (en) * | 2002-10-09 | 2002-11-13 | Angiogene Pharm Ltd | Combination therapy |
FR2848212B1 (fr) * | 2002-12-06 | 2006-10-27 | Aventis Pharma Sa | Derives de la colchicine, procede de preparation, produits obtenus par ce procede et utilisation |
WO2004112801A2 (en) * | 2003-06-18 | 2004-12-29 | Angiogene Pharmaceuticals Limited | Compositions comprising zd6126 together with 5-fu, cpt-11 or 5-fu and cpt-11 having vascular damaging activity for treating e.g. colorectal cancer |
GB0316123D0 (en) * | 2003-07-10 | 2003-08-13 | Astrazeneca Ab | Combination therapy |
GB0316127D0 (en) * | 2003-07-10 | 2003-08-13 | Astrazeneca Ab | Combination therapy |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RO86439B (ro) * | 1982-01-15 | 1985-03-31 | Eli Lilly And Company | Procedeu pentru prepararea unor derivati de acid ascorbic |
US4996237A (en) * | 1987-01-06 | 1991-02-26 | Arizona Board Of Regents | Combretastatin A-4 |
AU6605690A (en) * | 1989-10-27 | 1991-05-31 | Du Pont Merck Pharmaceutical Company, The | Monoclonal antibodies to basic fibroblast growth factor that inhibit its biological activity |
DE69105495T2 (de) * | 1990-04-02 | 1995-04-06 | Pfizer | Benzylphosphonsäure-tyrosinkinaseinhibitoren. |
JPH06503095A (ja) * | 1991-05-29 | 1994-04-07 | ファイザー・インコーポレーテッド | 三環式ポリヒドロキシ系のチロシンキナーゼ阻害薬 |
US5561122A (en) * | 1994-12-22 | 1996-10-01 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Combretastatin A-4 prodrug |
GB9714249D0 (en) * | 1997-07-08 | 1997-09-10 | Angiogene Pharm Ltd | Vascular damaging agents |
JPH11228594A (ja) * | 1998-02-16 | 1999-08-24 | Meiji Milk Prod Co Ltd | 新規プロゲステロン化合物 |
WO2000076497A1 (en) * | 1999-06-14 | 2000-12-21 | Cancer Research Ventures Limited | Cancer therapy |
US20040067255A1 (en) * | 2002-10-07 | 2004-04-08 | Chaplin David J. | Method of administering split doses of a vascular targeting agent |
-
2001
- 2001-03-27 MX MXPA02009603A patent/MXPA02009603A/es unknown
- 2001-03-27 PT PT01915495T patent/PT1272200E/pt unknown
- 2001-03-27 PL PL01357282A patent/PL357282A1/xx not_active Application Discontinuation
- 2001-03-27 JP JP2001572112A patent/JP2003528921A/ja active Pending
- 2001-03-27 CN CN01807663A patent/CN1422157A/zh active Pending
- 2001-03-27 CZ CZ20023231A patent/CZ20023231A3/cs unknown
- 2001-03-27 EE EEP200200549A patent/EE200200549A/et unknown
- 2001-03-27 ES ES01915495T patent/ES2243466T3/es not_active Expired - Lifetime
- 2001-03-27 WO PCT/GB2001/001329 patent/WO2001074369A1/en not_active Application Discontinuation
- 2001-03-27 HU HU0300576A patent/HUP0300576A3/hu unknown
- 2001-03-27 US US10/239,898 patent/US20030055024A1/en not_active Abandoned
- 2001-03-27 DE DE60111622T patent/DE60111622T2/de not_active Expired - Fee Related
- 2001-03-27 BR BR0109671-0A patent/BR0109671A/pt not_active IP Right Cessation
- 2001-03-27 IL IL15162701A patent/IL151627A0/xx unknown
- 2001-03-27 KR KR1020027012915A patent/KR20020084267A/ko not_active Application Discontinuation
- 2001-03-27 EP EP01915495A patent/EP1272200B1/en not_active Expired - Lifetime
- 2001-03-27 AU AU4258601A patent/AU4258601A/xx active Pending
- 2001-03-27 AU AU2001242586A patent/AU2001242586B2/en not_active Ceased
- 2001-03-27 SK SK1390-2002A patent/SK13902002A3/sk unknown
- 2001-03-27 AT AT01915495T patent/ATE298240T1/de not_active IP Right Cessation
- 2001-03-27 CA CA002402078A patent/CA2402078A1/en not_active Abandoned
- 2001-03-27 NZ NZ534190A patent/NZ534190A/en unknown
-
2002
- 2002-09-19 IS IS6555A patent/IS6555A/is unknown
- 2002-09-30 NO NO20024683A patent/NO20024683L/no unknown
Also Published As
Publication number | Publication date |
---|---|
WO2001074369A1 (en) | 2001-10-11 |
AU4258601A (en) | 2001-10-15 |
ATE298240T1 (de) | 2005-07-15 |
HUP0300576A2 (hu) | 2003-07-28 |
NZ534190A (en) | 2007-05-31 |
IS6555A (is) | 2002-10-18 |
EP1272200B1 (en) | 2005-06-22 |
CA2402078A1 (en) | 2001-10-11 |
NO20024683D0 (no) | 2002-09-30 |
JP2003528921A (ja) | 2003-09-30 |
SK13902002A3 (sk) | 2003-05-02 |
EP1272200A1 (en) | 2003-01-08 |
KR20020084267A (ko) | 2002-11-04 |
IL151627A0 (en) | 2003-04-10 |
CN1422157A (zh) | 2003-06-04 |
NO20024683L (no) | 2002-10-15 |
CZ20023231A3 (cs) | 2003-01-15 |
PL357282A1 (en) | 2004-07-26 |
AU2001242586B2 (en) | 2004-12-16 |
PT1272200E (pt) | 2005-09-30 |
DE60111622D1 (de) | 2005-07-28 |
HUP0300576A3 (en) | 2005-02-28 |
BR0109671A (pt) | 2003-02-04 |
MXPA02009603A (es) | 2004-05-14 |
DE60111622T2 (de) | 2006-05-18 |
ES2243466T3 (es) | 2005-12-01 |
US20030055024A1 (en) | 2003-03-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PT1223980E (pt) | Utilizacao de inibidores de csf-1 | |
HK1078771A1 (en) | Use of the quinazoline derivative zd6474 combined with gemcitabine and optionally ionising radiationin the treatment of cancer | |
ZA200802811B (en) | Therapy for the treatment of disease | |
BRPI0412426A (pt) | uso da zd6474 ou de um sal farmaceuticamente aceitável da mesma e de um agente antitumoral de platina, composição farmacêutica, kit, e método para a produção de um efeito antiangiogênico e/ou redutor de permeabilidade vascular em um animal de sangue quente | |
NO20032027D0 (no) | Effektive antitumorbehandlinger | |
MXPA04004355A (es) | Tratamiento de combinacion que comprende zd6474 y un taxano. | |
NO20024646D0 (no) | Kombinasjonsterapier med vaskul¶r-skadende aktivitet | |
NZ517038A (en) | Use of serotonin reuptake inihibitor in medicaments for treating sexual dysfunction | |
NZ591525A (en) | Methods of treatment of complicated skin and skin structure infections using single doses of oritavancin | |
BRPI0508982A (pt) | uso de azd2171 ou de um sal deste farmaceuticamente aceitável excluindo um sal de maleato de azd2171, composição farmacêutica, kit, método para o tratamento de um cáncer em um animal de sangue quente tal como um ser humano, e, uso de sal de maleato de azd2171 e 5 - fu e cpt - 11 | |
EE200200549A (et) | Jagatud doosi teraapia veresooni kahjustava aktiivsusega | |
BRPI0508983A (pt) | uso de azd2171 ou de um sal deste farmaceuticamente aceitável excluido um sal de maleato de azd2171 e um taxano, composição farmacêutica, kit, e, método para a produção de efeito antiangiogênico e/ou de redução da permeabilidade vascular em um animal de sangue quente tal como um ser humano | |
BRPI0412408A (pt) | métodos para a produção de um efeito de redução antiangiogênico e/ou de permeabilidade vascular e para o tratamento de um cáncer em um animal de sangue quente tal como um ser humano, composição farmacêutica, kit, e uso de azd2171 ou um sal farmaceuticamente aceitável deste e zd1839 ou um sal farmaceuticamente aceitável deste | |
ATE345805T1 (de) | Calciumtrifluoracetat mit zytotoxischer wirkung | |
BRPI0412450A (pt) | métodos para a produção de um efeito de redução antiangiogênico e/ou de permeabilidade vascular em um animal de sangue quente tal como um ser humano, e para o tratamento de um cáncer, composição farmacêutica, kit, e, uso de azd2171 ou um sal farmaceuticamente aceitável deste e zd6126 ou um sal farmaceuticamente aceitável deste | |
NO20043774L (no) | The use of devazenide as analgesic agent | |
DE60308403D1 (de) | Kombinationstherapie mit gemzitabin und zd6126 | |
RU2002129097A (ru) | Комбинированные терапии с использованием активности, повреждающей сосуды | |
RU2003110183A (ru) | Способ лечения рассеянного склероза |